<DOC>
	<DOCNO>NCT01691989</DOCNO>
	<brief_summary>This multicenter , randomize , double-blind , placebo-controlled study ass efficacy , safety tolerability aleglitazar compare placebo add sulfonylurea monotherapy sulfonylurea plus metformin combination therapy patient type 2 diabetes mellitus inadequately control sulfonylurea alone sulfonylurea plus metformin therapy . Patients randomize receive oral dos 150 mcg aleglitazar daily placebo . The anticipated time study treatment 26 week .</brief_summary>
	<brief_title>A Study Aleglitazar Combination With Metformin Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Sulfonylurea Alone Sulfonylurea Plus Metformin Therapy</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Adult patient , &gt; /=18 year age Diagnosis diabetes mellitus , type 2 Patients treat stable sulfonylurea monotherapy sulfonylurea plus metformin combination therapy least 12 week prior screen HbA1c &gt; /=7 % &lt; /=9.5 % screen within 4 week prior screen prerandomization visit Fasting plasma glucose &lt; /=240 mg/dL prerandomization visit Agreement maintain diet exercise habit study Patients Type 1 diabetes mellitus , secondary diabetes , diabetes result pancreatic injury , acute metabolic diabetic complication within past 6 month Any previous treatment thiazolidinedione dual PPAR agonist Any body weight lower lipoproteinmodifying therapy within 12 week prior screen ( except stable dose statin ) Any antihyperglycemic medication sulfonylurea alone combination metformin within 12 week prior screen Symptomatic congestive heart failure classify New York Heart Association class IIIV screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>